Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Paricalcitol
Drug ID BADD_D01676
Description Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.
Indications and Usage For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4
Marketing Status approved; investigational
ATC Code H05BX02
DrugBank ID DB00910
KEGG ID D00930
MeSH ID C084656
PubChem ID 5281104
TTD Drug ID D0N1TP
NDC Product Code 0074-1658; 0074-4637; 0074-9036; 0143-9624; 65162-823; 65862-936; 70121-1035; 43598-565; 55150-213; 67457-379; 66499-0019; 16729-311; 43598-562; 55150-215; 68382-331; 65862-938; 67457-692; 69452-147; 10888-8103; 10888-8104; 11014-0334; 48943-0033; 58032-1001; 68513-1054; 49483-689; 55150-212; 68382-330; 69452-145; 70121-1033; 70121-1034; 10888-8102; 14474-021; 0143-9625; 49483-687; 65862-937; 11014-0048; 55111-663; 70121-1036; 58272-192; 0074-9037; 43598-563; 49483-688; 55111-665; 63629-2452; 67457-380; 16729-310; 25000-017; 0143-9596; 55150-214; 63629-2453; 65162-822; 67457-389; 69452-146; 25000-014; 43598-564; 55111-664; 65162-824; 11014-0053; 25000-012
UNII 6702D36OG5
Synonyms paricalcitol | 19-nor-1alpha,25-dihydroxyvitamin D2 | 19-nor-1,25-(OH)2D2 | Zemplar | paricalcitol-d6
Chemical Information
Molecular Formula C27H44O3
CAS Registry Number 131918-61-1
SMILES CC(C=CC(C)C(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3)O)O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Glaucoma06.03.01.002--
Haemorrhagic stroke24.07.04.014; 17.08.01.0110.025507%Not Available
Headache17.14.01.001--
Heart rate irregular13.14.04.003--Not Available
Hirsutism23.02.04.001; 05.05.01.005--
Hypercalcaemia14.04.01.003; 05.04.01.0020.026488%
Hypercholesterolaemia14.08.01.001--Not Available
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperkalaemia14.05.03.001--
Hyperparathyroidism14.04.01.020; 05.04.01.001--
Hyperphosphataemia14.04.03.0070.011969%
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypertensive crisis24.08.01.0010.006867%Not Available
Hypertensive heart disease02.11.02.001; 24.08.05.0020.002943%Not Available
Hypervolaemia14.05.06.003; 02.05.04.019--Not Available
Hypoaesthesia23.03.03.081; 17.02.06.023--Not Available
Hypocalcaemia14.04.01.004--
Hypoglycaemia14.06.03.001; 05.06.03.001--
Hypoparathyroidism12.02.15.001; 05.04.02.001; 14.04.01.007--
Hypotension24.06.03.002--
Hypovolaemia14.05.05.0020.001962%Not Available
Hypovolaemic shock24.06.02.0170.008829%Not Available
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.002--Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
Injection site extravasation12.07.03.002; 08.02.03.002--Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Insomnia17.15.03.002; 19.02.01.002--
Intestinal ischaemia24.04.08.001; 07.15.02.001--Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 9 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene